885521-22-2

Basic information

• Product Name: 3-IODO-4-NITRO (1H)INDAZOLE
• Synonyms: 3-IODO-4-NITRO (1H)INDAZOLE;3-Iodo-4-nitro-1H-indazol...;3-iodo-4-nitro-2H-indazole
• CAS NO: 885521-22-2
• Molecular Formula: C₇H₄IN₃O₂
• Molecular Weight: 289.03
• Mol File: 885521-22-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 210-212°
• Boiling Point: 458.0±25.0 °C(Predicted)
• Appearance: /
• Density: 2.240±0.06 g/cm3(Predicted)
• Refractive Index: 1.818
• PKA: 9.12±0.40(Predicted)
• CAS DataBase Reference: 3-IODO-4-NITRO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IODO-4-NITRO (1H)INDAZOLE(885521-22-2)
• EPA Substance Registry System: 3-IODO-4-NITRO (1H)INDAZOLE(885521-22-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 885521-22-2(Hazardous Substances Data)

Usage

General Description

3-IODO-4-NITRO (1H)INDAZOLE is a chemical compound that belongs to the indazole family and is characterized by a nitro group and an iodo substituent. It is commonly used in research and laboratory settings as a building block or intermediate for the synthesis of various organic compounds and pharmaceuticals. This chemical has been studied for its potential as an antimicrobial and antitumor agent due to its ability to inhibit specific biological pathways and processes. Its unique structural properties and versatile reactivity make it a valuable tool for the development of new drugs and materials in the field of medicinal chemistry and chemical biology. However, caution must be exercised when handling this compound due to its potential toxicity and environmental impact.

InChI:InChI=1/C7H4IN3O2/c8-7-6-4(9-10-7)2-1-3-5(6)11(12)13/h1-3H,(H,9,10)

Upstream product

• 2942-40-7 nitro-4 indazole 

Downstream Products

• 1313409-98-1 3-iodo-1-((1-(4-methoxybenzyl)-1H-pyrazol-5-yl)methyl)-4-nitro-1H-indazole 
• 1313409-75-4 3-iodo-1-((1-(4-methoxybenzyl)-1H-pyrazol-4-yl)methyl)-4-nitro-1H-indazole 
• 1313407-32-7 N-(1-benzyl-5-chloro-3-ethyl-1H-indazol-4-yl)-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide 
• 1313409-12-9 1-benzyl-5-chloro-3-ethyl-1H-indazol-4-amine 
• 1313407-30-5 N-(1-benzyl-3-ethyl-1H-indazol-4-yl)-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide 
• 1313409-06-1 1-benzyl-3-ethyl-1H-indazol-4-amine 
• 1313409-05-0 1-benzyl-3-ethyl-4-nitro-1H-indazole 
• 1313407-29-2 N-(1-benzyl-3-iodo-1H-indazol-4-yl)-7-(2-methoxyethoxy)imidazo[1,2-a]pyridine-3-carboxamide 
• 1313409-04-9 1-benzyl-3-iodo-1H-indazol-4-amine 
• 1313410-00-2 N-(3-ethyl-1-((1-(4-methoxybenzyl)-1H-pyrazol-5-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1313410-01-3 3-ethyl-1-((1-(4-methoxybenzyl)-1H-pyrazol-5-yl)methyl)-1H-indazol-4-amine 
• 1313409-99-2 1-((1-(4-methoxybenzyl)-1H-pyrazol-5-yl)methyl)-4-nitro-3-vinyl-1H-indazole 
• 1313407-50-9 N-(3-ethyl-1-((1-(4-methoxybenzyl)-1H-pyrazol-4-yl)methyl)-1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1313409-79-8 C₂₉H₂₅N₇O₂ 

Relevant articles and documents

SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal

Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists

As part of our efforts to develop agents for cognitive enhancement, we have been focused on the 5-HT6 receptor in order to identify potent and selective ligands for this purpose. Herein we report the identification of a novel series of 3-sulfonylindazole derivatives with acyclic amino side chains as potent and selective 5-HT6 antagonists. The synthesis and detailed SAR of this class of compounds are reported.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.